# Biotech Growth Trust shares rise 22.9% as five portfolio companies agree takeovers

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-shares-rise-22-9-as-five-portfolio-companies-agree-takeovers/4121269896
- Published: 2026-11-17T07:05:00+00:00
- Author: Amilia Stone

**Biotech Growth Trust PLC** (LON:BIOG) has announced its Unaudited Results for 
the Six Months ended 30 September 2026

The statements below are extracted from the Company’s half-yearly report for the
six months ended 30 September 2026. This announcement contains references to graphs
and charts which appear in the full Half Year Report, which will shortly be available
on the Company’s website at www.biotechgt.com. Up to date information on the Company,
including daily NAVs, share prices and monthly fact sheets, can also be found on
the website.

The Half Year Report has been submitted to the Financial Conduct Authority, and 
will shortly be available for inspection on the National Storage Mechanism (NSM)
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

**COMPANY PERFORMANCE**

**KEY STATISTICS**

|   | **As at** | **As at** |   | 
|   | **30 September** | **31 March** | **%** | 
|   | **2026** | **2026** | **Change** | 
| Net asset value (“NAV”) per share | 1,623.8p | 1,414.6p | 14.8% | 
| Share price | 1,548.0p | 1,260.0p | 22.9% | 
| NASDAQ Biotechnology Index (Benchmark) | – | – | 21.6% | 
| Discount of share price to NAV per share^ | 4.7% | 10.9% |   | 
| (Net cash)/gearing^ | (5.2%) | 3.3% |   | 
| Ongoing Charges^ | 1.2% | 1.2% |   | 
| Active Share*^ | 78.9% | 80.8% |   |

^ Alternative Performance Measure (see Glossary in the Half Year Report)

* Source: Frostrow Capital LLP

**PERFORMANCE HIGHLIGHTS:**

 * Over the reporting period:
    - NAV per share total return of 14.8%, from 1,414.6p to 1,623.8p
    - Share price total return of 22.9%, from 1,260.0p to 1,548.0p
    - The NASDAQ Biotechnology Index (the Benchmark) gained 21.6% (total return,
      net of withholding tax, sterling adjusted)
    - The discount of the share price to NAV per share narrowed from 10.9% to 4.7%
    - The Company bought back 1,114,074 shares at an average discount of 9.0%, at
      a cost of £15.7m, representing 5.6% of the shares in issue at the start of
      the period. Buybacks contributed 0.5% to the NAV return
    - Five portfolio companies agreed to be acquired during the period
    - Gearing was reduced to nil by 30 September 2026, with net cash of 5.2% at 
      the period end

> **Roger Yates, Chair, commented:**
> “The Company delivered a strong absolute return during the period, and the share
> price total return of 22.9% outpaced the Benchmark. The NAV’s relative underperformance
> occurred largely during the sharp market downturn in September. The biotechnology
> sector benefitted from improving investor sentiment through much of the summer,
> supported by encouraging clinical data, a more active capital markets environment
> and continued evidence of scientific innovation across the industry. However, 
> the rapid rise in U.S. Treasury yields and renewed inflation concerns during September
> led to a significant sell-off in small-cap biotechnology stocks, which disproportionately
> affected the Company’s portfolio given its longstanding emphasis on this part 
> of the market. In response to these changing market conditions, the Portfolio 
> Manager undertook a number of repositioning measures, including rebalancing the
> portfolio and reducing gearing, which helped to mitigate, though not eliminate,
> the impact of the market weakness.
> The Company’s strategic allocation to small-cap biotechnology companies contributed
> significantly to outperformance during the previous financial year and reflects
> the Portfolio Manager’s conviction that smaller companies remain the primary source
> of innovation within the sector, offering attractive long-term valuation opportunities.
> While this approach detracted from relative returns during the latter part of 
> the period, the Board remains supportive of a strategy that seeks to identify 
> the industry’s future winners at an earlier stage of their development.
> Several holdings delivered excellent returns, notably Forte Biosciences, UroGen
> Pharma and Kiniksa Pharmaceuticals, each benefitting from a combination of positive
> clinical results, strong commercial execution and corporate activity. More broadly,
> the Company benefitted from healthy merger and acquisition (“M&A”) activity across
> the sector, with five portfolio companies agreeing to be acquired during the period.
> The discount of the share price to NAV per share narrowed from 10.9% to 4.7% over
> the period, supported by the Company’s ongoing buyback programme, which added 
> 0.5% to the NAV return.
> While short-term market movements are difficult to predict, the Board retains 
> confidence in the Portfolio Manager’s disciplined investment approach and deep
> sector expertise, as they continue to demonstrate their ability to identify innovative
> biotech companies with attractive long-term prospects.
> Biotechnology has always been a sector characterised by periods of both exceptional
> opportunity and considerable volatility. Although we remain mindful of the risks
> inherent in the sector and the potential for further short-term volatility, we
> believe the fundamental outlook for the portfolio remains encouraging and we are
> confident that the Company will be able to participate in the long-term growth
> of this dynamic sector.”

> **Geoff Hsu, Lead Portfolio Manager, BIOG, commented:**
> “The Company’s underperformance relative to the Benchmark during the review period
> was principally attributable to its significant weighting in smaller-cap biotech
> stocks. Small-cap biotech stocks outperformed large-cap stocks for much of the
> review period before the trend reversed during the final two months of the period.
> Although the Company typically operates with gearing between 5-10% of NAV, we 
> actively reduced gearing to zero by the end of the period to better manage the
> dramatic volatility in September.
> M&A activity continued across the sector during the review period, with particularly
> strong activity in the opening months before dealmaking came to a standstill in
> August and September. Dealmaking began to pick up again after the period end, 
> with two transactions exceeding $1 billion in early October. We believe the recent
> correction in biotech valuations could lead to an acceleration in M&A activity
> as large pharmaceutical companies seek to augment revenue growth ahead of patent
> cliffs in the early part of the next decade.
> We remain optimistic about the biotech sector given the industry’s strong fundamentals
> and valuations that remain below historical norms. The FDA continues to approve
> drugs at an elevated pace, with a number of newly launched initiatives poised 
> to accelerate drug development timelines, and we anticipate that the incoming 
> commissioner will bring continued stability to the agency. Meanwhile, the prospect
> of further government intervention in U.S. drug pricing appears to have diminished
> in the near term.
> We continue to emphasise small- and mid-cap companies in the portfolio as we believe
> they offer the greatest opportunity for investment upside. As sector volatility
> increased towards the end of the review period, we adopted more conservative positioning,
> but will continue to look for opportunities to increase our exposure to small 
> and mid-cap investments once market conditions stabilise.”

**CHAIR’S STATEMENT**

**INTRODUCTION AND RESULTS**

In the first six months of this financial year, the Company’s NAV per share total
return^ was 14.8%, underperforming the increase of 21.6% in the NASDAQ Biotechnology
Index (total return, net of withholding tax, sterling adjusted) (the “Benchmark”).
The Company’s share price total return^ was 22.9%, benefitting from a narrowing 
of the discount to the NAV per share and modestly exceeding the Benchmark return.

Despite the relative underperformance of the NAV the Company delivered a strong 
absolute return during the period, with the majority of the underperformance against
the Benchmark occurring during the sharp market downturn in September. The biotechnology
sector benefitted from improving investor sentiment through much of the summer, 
supported by encouraging clinical data, a more active capital markets environment
and continued evidence of scientific innovation across the industry. However, the
rapid rise in U.S. Treasury yields and renewed inflation concerns during September
led to a significant sell-off in small-cap biotechnology stocks, which disproportionately
affected the Company’s portfolio given its longstanding emphasis on this part of
the market. As these changes in market conditions started to unfold, the Portfolio
Manager undertook a number of repositioning measures, including rebalancing the 
portfolio and reducing gearing, which helped to mitigate, though not eliminate, 
the impact of the market weakness.

The Company’s strategic allocation to small-cap biotechnology companies contributed
significantly to outperformance during the previous financial year and reflects 
the Portfolio Manager’s conviction that smaller companies remain the primary source
of innovation within the sector, offering attractive long-term valuation opportunities.
While this approach detracted from relative returns during the latter part of the
period, the Board remains supportive of a strategy that seeks to identify the industry’s
future winners at an earlier stage of their development.

Several holdings delivered excellent returns, notably Forte Biosciences, UroGen 
Pharma and Kiniksa Pharmaceuticals, each benefitting from a combination of positive
clinical results, strong commercial execution or corporate activity. More broadly,
the Company benefitted from healthy merger and acquisition activity across the sector,
with five portfolio companies agreeing to be acquired during the period.

The principal detractors from performance were Relmada Therapeutics, Alnylam Pharmaceuticals
and Evommune, which were adversely affected by development delays, reduced commercial
expectations and disappointing clinical trial results, respectively. In general,
many pre-revenue biotechnology companies experienced sharp valuation declines during
September as rising interest rates reduced investor appetite for longer-duration
growth assets.

The presence of gearing over the period contributed 0.7% to the Company’s NAV performance.
Reflecting increased market volatility, gearing was reduced to nil by 30 September
2026. We view this as a good example of the active risk management that underpins
the investment process and demonstrates the flexibility available to the Portfolio
Manager when market conditions warrant a more cautious stance.

The Company’s NAV return was dampened by the increase in sterling over the period
by 0.7% against the U.S. dollar, being the currency in which the majority of the
Company’s investments are denominated.

A comprehensive explanation of performance over the period is set out in the Portfolio
Manager’s Review.

**SHARE PRICE PERFORMANCE**

As noted at the outset, the discount^ of the share price to the NAV per share narrowed
over the period: at 31 March 2026, the discount was 10.9% and at 30 September, 4.7%.
This meant that the share price return^ over the six months was 22.9%, exceeding
both the NAV and the Benchmark returns.

Shareholders will be aware that the Company pursues an active discount management
policy, buying back shares when the discount of the Company’s share price to the
NAV per share is higher than 6%. Accordingly, during the period the Company bought
back 1,114,074 shares at an average discount of 9.0% to the NAV per share, at a 
cost of £15.7m. At the period end there were 18,815,240 shares in issue and, as 
noted above, the share price traded at a 4.7% discount to the NAV per share. Share
buybacks contributed 0.5% to the Company’s NAV return during the period, equivalent
to around 40% of the Company’s annual ongoing charges, highlighting the value created
through disciplined discount management.

Shareholders should note that the shares can trade at a discount wider than 6%, 
particularly in volatile markets or in periods of muted demand for the Company, 
the investment trust sector or for equities in general. Furthermore, during periods
of rapid NAV appreciation or depreciation it is not uncommon for the share price
to lag temporarily, reflecting the time it takes for market sentiment and trading
activity to adjust to the underlying portfolio performance.

The Company remains committed to protecting a 6% share price discount over the long
term and at the annual general meeting in July shareholders approved the Board’s
proposal to renew the Company’s authority to buy back shares, with over 99% of the
votes received in favour of the proposal.

Since the period end a further 617,327 shares have been bought back for cancellation
and at the time of writing the share price discount stands at 5.9%.

**PERFORMANCE FEE**

There is no provision within the Company’s NAV for any performance fee payable at
a future calculation date. This is because the performance fee is dependent on the
Company’s long-term outperformance: a performance fee only becomes payable if and
when the Company’s cumulative outperformance gives rise to a performance fee that
exceeds the total of performance fees paid to date. This ensures that a performance
fee is not payable for any outperformance that contributes to recovery of prior 
performance.

**THE BOARD**

All resolutions at the AGM in July were passed by the requisite majority. However,
as noted in the results of the 2026 Annual General Meeting, the Board undertook 
to consult shareholders following a significant vote against the re-election of 
Geoff Hsu. The vote principally reflected the governance policies of a shareholder
concerning representatives of the portfolio manager sitting on investment trust 
boards. Having considered the feedback received from a range of shareholders and
as part of the Board’s ongoing succession planning, it has been agreed that Geoff
will retire from the Board at the conclusion of the AGM in 2027. Geoff will continue
in his role as lead portfolio manager and there will be no change to the management
of the Company’s portfolio. Geoff has served as a Director since 2018 and has made
a valuable contribution to the Board through his investment experience and market
insight, for which I would like to express the Board’s thanks.

**OUTLOOK**

The biotechnology sector remains one of the most innovative and exciting areas of
global equity markets. Across the industry, companies continue to advance new therapies
and technologies that have the potential to improve outcomes for patients and address
significant unmet medical needs. Scientific progress has continued despite a challenging
market backdrop, reinforcing our belief in the long-term value that innovation can
create for both society and investors. Recent regulatory approvals and continued
advances in areas such as gene and RNA-based therapies underline the breadth of 
opportunity within the sector.

At the same time, recent months have provided a timely reminder that biotechnology
investing rarely follows a straight path. Share prices are often influenced by factors
beyond company-specific developments, including changes in interest rate expectations,
capital market conditions, the evolving political and regulatory environment, and
broader investor sentiment. These influences can be particularly pronounced among
smaller biotechnology companies and can result in periods when market valuations
do not fully reflect underlying business progress.

While short-term market movements are difficult to predict, the Board retains confidence
in the Portfolio Manager’s disciplined investment approach and deep sector expertise,
as they continue to demonstrate their ability to identify innovative biotech companies
with attractive long-term prospects. The recent repositioning of the portfolio also
demonstrates OrbiMed’s active approach to risk management and capital allocation
in response to evolving market conditions.

Biotechnology has always been a sector characterised by periods of both exceptional
opportunity and considerable volatility. Although we remain mindful of the risks
inherent in the sector and the potential for further short-term volatility, we believe
the fundamental outlook for the portfolio remains encouraging and we are confident
that the Company will be able to participate in the long-term growth of this dynamic
sector.

**Roger Yates**

Chair

16 November 2026

_^Alternative Performance Measure._

[274236-biotech-growth-trust-interim-web](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/274236-biotech-growth-trust-interim-web.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/11/274236-biotech-growth-trust-interim-web.pdf)

Share on:
